Phage Lytic Enzyme Cpl-1 as a Novel Antimicrobial for Pneumococcal Bacteremia
Streptococcus pneumoniae is becoming increasingly antibiotic resistant worldwide, and thus new antimicrobials are badly needed. We report the use of Cpl-1, the lytic enzyme of a pneumococcal bacteriophage, as an intravenous therapy for pneumococcal bacteremia in a mouse model. A 2,000-μg dose of Cpl...
Збережено в:
| Опубліковано в:: | Infect Immun |
|---|---|
| Автори: | , , |
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
American Society for Microbiology (ASM)
2003
|
| Предмети: | |
| Онлайн доступ: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC219578/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/14573637/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/IAI.71.11.6199-6204.2003 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|